El interés en corto de Sangamo Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Sangamo Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Sangamo Therapeutics (NASDAQ:SGMO) Bolsa, Informe de interés en corto

Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

WIIM

Sangamo Therapeutics shares are trading higher after the company announced it licensed its STAC-BBB technology to Astellas to drive genomic medicine for neurological diseases.

U.S. stock futures climbed on Thursday in premarket hours after the indices declined in the previous session following a <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">hawkish cut</a> from the Federal Reserve. The futures of all four major indices were trading higher.
The 10-year and two-year Treasury notes yielded 4.54% and 4.32%, respectively.
On Wednesday, the Federal Reserve did reduce interest rates by 0.25% to a range of 4.25%-4.5%, as expected. However, the revised economic projections indicate only two possible rate cuts in 2025—down from the four predicted in September and fewer than the three that markets had anticipated before the meeting.
The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 91.4%, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according</a> to CME Group&#8217;s FedWatch tool.
GDP revisions slated to be released later today will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.28%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.37%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.39%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.52% to $589.35 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.48% to $518.94, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
U.S. stocks closed lower on Wednesday, with the <a href="https://www.benzinga.com/news/earnings/24/12/42569953/dow-dips-over-1100-points-falling-for-10th-session-as-powell-adopts-hawkish-stance-greed-index-moves-to-fear-zone">Dow Jones dropping for the tenth consecutive session</a>, falling by more than 1,100 points.
On the economic front, the U.S. posted a current account deficit of $310.9 billion in the third quarter, up from a revised deficit of $275.0 billion in the previous quarter and exceeding market expectations of a $284 billion gap. Meanwhile, U.S. housing starts declined by 1.8%, reaching an annualized rate of 1.289 million units in November, down from 1.312 million in October.
All sectors of the S&amp;P 500 ended the day in the red, with consumer discretionary, real estate, and communication services stocks seeing the largest losses.
&#8220;It&#8217;s been a very mild year with just 17 declines of 1% or more,&#8221; said Charlie Bilello, chief market strategist at Creative Planning Investor.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 fell 2.95% today, the worst day for stocks since August 5 (Nikkei black Monday crash). Overall, it&#39;s been a very mild year with just 17 declines of 1% or more (vs. 29 in the average year). History of large down days since 1928&#8230; <a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a><a href="https://t.co/l5IYmkf6Ih">https://t.co/l5IYmkf6Ih</a> <a href="https://t.co/XSAGBsgiIY">pic.twitter.com/XSAGBsgiIY</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1869527952851116382?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-3.56%</td>
<td>19,392.69</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-2.95%</td>
<td>5,872.16</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-2.58%</td>
<td>42,326.87</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-4.39%</td>
<td>2,231.51</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Talking about her 2025 projections after the Fed&#8217;s rate cut, Julia Khandoshko, the CEO of Mind Money in a conversation with <a href="https://www.benzinga.com">Benzinga</a> said, &#8220;In 2025, investors should focus on three key strategies: monitoring the impact of political and economic changes on markets, investing in promising sectors such as AI and biotechnology without excessive dependence on technology, and actively diversifying the portfolio with traditional industries and new opportunities in emerging markets.&#8221;
Chris Zaccarelli, chief investment officer for Northlight Asset Management, said that markets are forward-looking and reacted to the Fed&#8217;s 2025 projection and not the quarter-point cut that it delivered.
&#8220;Santa came early and dropped a 25-bps rate cut in the market&#8217;s stocking but accompanied it with a note saying that there would be coal next year,&#8221; Zaccarelli said.
Jeremy Siegel, professor emeritus at the University of Pennsylvania's Wharton School, described the stock market's recent downturn as a "healthy" reaction to the Federal Reserve's cautious approach to future interest rate cuts.
&#8220;The market was overly optimistic…so I am not surprised at the sell-off,&#8221; he said.
He suggested that the Fed might reduce rates only once or twice next year, with the possibility of no cuts at all due to inflation concerns. Siegel also mentioned potential tariffs from President-elect Donald Trump could impact inflation, though he believes the actual tariffs may not be as significant as feared.
Bill Adams, chief economist for Comerica Bank, said the Fed is reacting to the incoming Trump administration&#8217;s policies, which it sees as most likely to boost growth and inflation, as well as tighten the job market.
Trump does not have much control over the pace of rate cuts in the near term, Adams said, but &#8220;that could change in 2026 if President-elect Trump gets the Senate to confirm a new Fed chair who is more sympathetic to his policy goals.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released in the rest of the week that will help investors determine the future course of action.
<ul>
<li>On Thursday, the data for initial jobless claims till Dec. 14, GDP&#8217;s second revision for the third quarter, and Philadelphia Fed manufacturing survey data for December will be released at 8:30 a.m., ET.</li>
<li>Existing home sales data and U.S. leading economic indicators for November will be announced at 10:00 a.m., ET.</li>
<li>On Friday, personal income and spending data along with core and headline PCE index data for November will be released at 8:30 a.m., ET.</li>
<li>Consumer sentiment data for December will be released at 10:00 a.m., ET.</li>
<li>Carnival Corporation and Winnebago Industries will report earnings.</li>
</ul>
Stocks In Focus:
<ul>
<li>Accenture Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) was up 3.56% ahead of its Q1 earnings call scheduled before the opening bell. Wall Street expects quarterly earnings at $3.40 per share on revenue of $17.12 billion.</li>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) was down 15.52% after it posted better-than-expected earnings but sales missed expectations in the first quarter.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) was just up 0.4% in premarket a analysts expect it to post quarterly earnings at 64 cents per share on revenue of $12.13 billion after the closing bell.</li>
<li>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) was 8.85% lower in premarket trading after it reported worse-than-expected financial results for the fourth quarter.</li>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) was up 22.55% after it inked an agreement with Astellas Pharma allowing the latter to leverage Sangamo&#8217;s novel proprietary neurotropic adeno-associated virus capsid. Sangamo will receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees.</li>
<li>KULR Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) was up 27.88% after it announced plans to launch the KULR ONE Space battery via launch integrator Exolaunch on a SpaceX rideshare mission scheduled for 2026.</li>
<li>Mesoblast Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 42.61% in pre-market trading after Mesoblast's RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.94% to hover around $69.92 per barrel.
The gold spot index fell by 0.82% to $2,631.59 per ounce. The Dollar Index was down 0.12% to 107.893 level.
Asian markets declined on Thursday, as Hong Kong&#8217;s Hang Seng, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and Australia&#8217;s ASX 200 index fell, while China&#8217;s CSI 300 index ended marginally higher.
Most European markets were also trading lower.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42571821/why-sangamo-therapeutics-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket">Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Market Summary

Futures

Economics

Federal Reserve

US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/SGMO/news">pre-market trading</a>.
Astellas and Sangamo Therapeutics disclosed Capsid license agreement to deliver genomic medicines for neurological diseases.
Sangamo Therapeutics shares jumped 19.5% to $2.81 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) gained 219.5% to $6.39 in pre-market trading after jumping 54% on Wednesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) climbed 170% to $2.13 in pre-market trading after declining over 50% on Wednesday.</li>
<li>AppTech Payments Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) gained 170% to $1.03 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) gained 68% to $3.55 in pre-market trading after dropping 26% on Wednesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 44.5% to $17.70 in pre-market trading. Mesoblast&#8217;s RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
<li>Elevai Labs Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 38.6% to $2.98 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Dallasnews Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) gained 38% to $6.72 in pre-market trading after falling 5% on Wednesday.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) rose 28% to $2.68 in pre-market trading after jumping 44% on Wednesday.</li>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) gained 24.2% to $2.67 in pre-market trading after dipping more than 90% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 40.5% to $0.4847 in pre-market trading after jumping 348% on Wednesday.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) declined 36.4% to $0.42 in pre-market trading after jumping more than 80% on Wednesday.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) shares fell 20.5% to $6.00 in pre-market trading.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares dipped 18.6% to $63.50 in pre-market trading as the company posted downbeat quarterly results and lowered FY25 outlook.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) fell 18.5% to $0.5213 in today's pre-market trading after jumping 52% on Wednesday.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) dipped 15.6% to $87.60 in pre-market trading. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) fell 15.6% to $2.00 in pre-market trading after surging 39% on Wednesday.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares fell 14.5% to $2.95 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) fell 14.3% to $0.3008 in pre-market trading following a 30% plunge on Wednesday.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 14.2% to $5.10 in pre-market trading after declining 5% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets
- Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales

Sangamo Licenses STAC-BBB Technology To Astellas To Drive Genomic Medicine For Neurological Diseases

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target <a href="https://www.benzinga.com/markets/equities/24/12/42505310/tesla-prepares-for-holiday-rush-tapping-into-global-supercharger-demand-to-drive-revenue-growth">from $400 to $515</a>.
Tesla shares gained 5% to $458.08 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares gained 59.6% to $1.5000.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares jumped 42.4% to $9.49.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) climbed 31.8% to $2.6950.</li>
<li>Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) gained 31.8% to $23.53 after the company announced Phase 3 results for its thyroid eye disease treatment trial.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) rose 25.5% to $8.99.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) gained 24.7% to $34.45 after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose 24.2% to $14.32 after the company announced it secured a $10 million order for AI semiconductor testing.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) climbed 19.8% to $25.08. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 18.4% to $7.26. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 15.5% to $8.14. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 13.4% to $30.99. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) gained 10.5% to $25.11. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Asana, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NASDAQ">ASAN</a>) gained 9.5% to $26.45.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) surged 9.1% to $42.54.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 7.6% to $242.06 on continued momentum from last week after the company reported earnings for the fourth-quarter.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 7% to $109.62.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42507587/tesla-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Intraday Update

AEHR

AGIO

ASAN

AVGO

BTDR

CIFR

EWTX

MARA

QUBT

RGTI

TSLA

VRDN

WULF

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday

Analysts' ratings for Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.17, accompanied by a high estimate of $10.00 and a low estimate of $5.00. Observing a 29.07% increase, the current average has risen from the previous average price target of $6.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1733860836_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Sangamo Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sangamo Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sangamo Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sangamo Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SGMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sangamo Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Sangamo Therapeutics Better</h2>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Sangamo Therapeutics: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Sangamo Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 425.77%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.99%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sangamo Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 29.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sangamo Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 9.19%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.71.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 6 Takes On Sangamo Therapeutics

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose sharply during Tuesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance with its <a href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more">midpoint above estimates.</a>
Smucker shares surged 6.2% to $120.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 59% to $7.55 after the company reported better-than-expected third-quarter sales results.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) gained 30.2% to $18.76 after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) surged 22.8% to $4.1750 after the company announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) gained 20.3% to $64.32 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its midpoint above estimates.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 18.1% to $22.17 after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.</li>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares rose 15% to $25.65.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) gained 13.8% to $1.8450.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 12.6% to $2.1850.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) surged 12.2% to $4.77. POET Technologies recently announced plans to expand its capacity.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares gained 9.1% to $125.10 after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) gained 8% to $99.21 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) surged 7.8% to $59.45. The company announced it will present 10 abstracts at SABCS.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) surged 7.4% to $192.62 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 7.3% to $25.82.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 5.8% to $8.94. UBS analyst Jay Sole upgraded Hanesbrands from Neutral to Buy and raised the price target from $9 to $11.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42190113/starbucks-to-rally-around-13-here-are-10-top-analyst-forecasts-for-tuesday">Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

ARWR

EMBC

EXAS

HSAI

NGNE

POET

RKLB

SMRT

SMTC

SRPT

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Sangamo Therapeutics shares are trading higher after the company announced it gained FDA clearance status for its IND application of ST-503 to treat idiopathic small fiber neuropathy.

Sangamo Therapeutics Gains FDA Clearance For IND Application Of ST-503 To Treat Idiopathic Small Fiber Neuropathy, Aiming To Address Chronic Neuropathic Pain With Phase 1/2 Study Enrollment Set For Mid-2025

Sangamo Therapeutics shares are trading lower. The company reported Q3 financial results

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.03) by 233.33 percent. This is a 106.78 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $49.41 million which beat the analyst consensus estimate of $17.94 million by 175.43 percent. This is a 425.77 percent increase over sales of $9.40 million the same period last year.

Earnings

Earnings Beats

Sangamo Therapeutics Q3 EPS $0.04 Beats $(0.03) Estimate, Sales $49.41M Beat $17.94M Estimate

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ZETA/earnings">third-quarter results</a>.
Total revenue rose 42% year-over-year to $268.3 million, while the company posted GAAP loss per share of 9 cents versus a year-ago loss of 27 cents per share.
Zeta Global shares dipped 9.8% to $33.15 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Destiny Tech100 Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>) declined 21.3% to $33.40 in pre-market trading after gaining 17% on Monday.</li>
<li>Agora, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) fell 13.8% to $4.32 in pre-market trading. Agora will release its financial results for the third quarter ended Sept. 30 after the closing bell on Nov. 25.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares declined 9.4% to $3.08 in pre-market trading after jumping over 25% on Monday.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell 8.5% to $2.47 in pre-market trading.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) fell 7.4% to $6.88 in pre-market trading.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) fell 7.2% to $9.79 in pre-market trading after jumping 32% on Monday.</li>
<li>Stepan Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) fell 5.5% to $75.14 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

DXYZ

OUST

SAVE

ZETA

Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Sangamo Therapeutics to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Sangamo Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 13.46% drop in the share price the next day.
Here's a look at Sangamo Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.21</td>
<td>-0.26</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-13.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>-22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731341104_0.png" alt="eps graph" />
<h3>Sangamo Therapeutics Share Price Analysis</h3>
Shares of Sangamo Therapeutics were trading at $2.87 as of November 08. Over the last 52-week period, shares are up 763.58%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Sangamo Therapeutics</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Sangamo Therapeutics.
The consensus rating for Sangamo Therapeutics is Buy, based on 4 analyst ratings. With an average one-year price target of $6.25, there's a potential 117.77% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Regenxbio and Y-mAbs Therapeutics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Regenxbio received a Buy consensus from analysts, with an average 1-year price target of $37.25, implying a potential 1197.91% upside.</li>
<li>Y-mAbs Therapeutics received a Outperform consensus from analysts, with an average 1-year price target of $21.0, implying a potential 631.71% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Regenxbio and Y-mAbs Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-25.11%</td>
<td>$-48M</td>
<td>-53.91%</td>
</tr>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-16.31%</td>
<td>$11.81M</td>
<td>-18.35%</td>
</tr>
<tr>
<td>Y-mAbs Therapeutics</td>
<td>Outperform</td>
<td>9.86%</td>
<td>$19.78M</td>
<td>-9.51%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sangamo Therapeutics ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance compared to its peers. However, it ranks in the middle for Return on Equity, suggesting average profitability. Overall, Sangamo Therapeutics lags behind its peers in terms of financial performance based on the provided metrics.
<h3>Delving into Sangamo Therapeutics's Background</h3>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Key Indicators: Sangamo Therapeutics's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, Sangamo Therapeutics faced challenges, resulting in a decline of approximately -94.79% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10148.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sangamo Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -89.89%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Sangamo Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -32.55%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Sangamo Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 1.23. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/SGMO/earnings">To track all earnings releases for Sangamo Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sangamo Therapeutics's Earnings Outlook

Sangamo Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $5 to $10.

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and raises the price target from $5 to $10.

HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Raises Price Target to $10

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Friday.
Shares of Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/10/41543105/government-and-military-contractor-booz-allen-clocks-strong-q2-performance-backlog-expands-to-41-3b">quarterly EPS and sales.</a>
Booz Allen Hamilton reported fiscal second-quarter adjusted EPS of $1.81, topping the analyst consensus estimate of $1.49. Quarterly sales of $3.15 billion, up 18% year-on-year, beat the street view of $2.97 billion. The backlog grew by 17.7%, reaching $41.3 billion, while the quarterly book-to-bill ratio stood at 2.61x.
Booz Allen Hamilton shares jumped 10% to $183.21 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares jumped 49.6% to $6.30. ImmunityBio recently announced it dosed its first patients in its Phase 1 clinical study of CAR-NK cell therapy for relapsed B-Cell Non-Hodgkin Lymphoma.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 32.4% to $29.50.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) climbed 22.8% to $8.81 after the company reported third-quarter financial results and raised its 2024 guidance.</li>
<li>ZEEKR Intelligent Technology Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NASDAQ">ZK</a>) gained 21.5% to $28.08.</li>
<li>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) gained 13.3% to $50.37 following a report alleging that a judge blocked the company&#8217;s proposed acquisition of Capri. The company issued a statement on the ruling saying it intends to appeal the decision.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose 11.7% to $1.6650.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 11.2% to $38.85.</li>
<li>AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) gained 10.4% to $211.98 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue guidance. Also, Piper Sandler maintained an Overweight rating on the stock.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) rose 10.2% to $167.53 after the company reported better-than-expected second-quarter financial results.</li>
<li>Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) gained 10.2% to $182.01 after the company reported better-than-expected third-quarter FFO results and raised its FY24 FFO guidance.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) gained 9.2% to $452.58 following strong quarterly sales.</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) surged 6.7% to $68.60 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<a href="https://www.benzinga.com/news/24/10/41545983/this-ppl-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday">This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday</a>

APPF

DECK

FTEL

IBRX

SAIA

Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday

Sangamo Biosciences ( ($SGMO) ) has shared an announcement. Sangamo Therapeutics faced legal challenges over a stock increase amendment, but the De...

Sangamo Biosciences' Legal Victory and Hemophilia Trial Success

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report), with a p...

Promising Trial Results and Strategic Partnerships Drive Buy Rating for Sangamo Biosciences

Sangamo Biosciences (SGMO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Nicole Germino f...

Sangamo Biosciences: Strategic Growth and Advancing Pipeline Drive Buy Rating

Truist upgraded Sangamo (SGMO) to Buy from Hold with a $7 price target The firm says that with the company's expenses streamlined, the shares could...

Sangamo upgraded to Buy from Hold at Truist

TD Cowen analyst Ritu Baral maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today. The company's shares closed yesterday at...

TD Cowen Sticks to Their Buy Rating for Sangamo Biosciences (SGMO)

Sangamo surges 24% after Roche ends development of hemophilia A gene therapy

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Comments

Sangamo Therapeutics

Interés en corto

Sangamo Therapeutics (NASDAQ:SGMO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL